Form 8-K - Current report:
SEC Accession No. 0000886163-26-000027
Filing Date
2026-04-30
Accepted
2026-04-30 16:41:14
Documents
11
Period of Report
2026-04-24
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20260424.htm   iXBRL 8-K 25318
  Complete submission text file 0000886163-26-000027.txt   140043

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20260424.xsd EX-101.SCH 1792
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20260424_lab.xml EX-101.LAB 21880
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20260424_pre.xml EX-101.PRE 12518
14 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20260424_htm.xml XML 2728
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 26926435
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)